Drugs / VRC-FLUDNA071-00-VP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02206464 | Jul 2014 → Jan 2016 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-FLUDNA071-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02206464 ↗ |
| Known as | H7 DNA Vaccine | “the H7 DNA Vaccine (DNA vaccine)” NCT02206464 ↗ |
| Modality | Vaccine | “The investigational VRC-FLUDNA071-00-VP vaccine was developed by VRC, NIAID” NCT02206464 ↗ |
| Route | Intramuscular | “H7 DNA vaccinations will be 4 mg administered as a 1 mL intramuscularly (IM)” NCT02206464 ↗ |